Selpercatinib Significantly Improves PFS, Responses in Advanced RET+ Medullary Thyroid Cancer
October 21, 2023Gina MauroSelpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients
Updated on: October 24,2023
2
Selpercatinib Significantly Improves PFS, Responses in Advanced RET+ Medullary Thyroid Cancer
October 21, 2023Gina MauroSelpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients
Updated on:October 24,2023
2
